Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

This trial tests a combination of two immunotherapy drugs — glofitamab and pirtobrutinib — in people with mantle cell lymphoma (a type of blood cancer) that has come back or stopped responding to treatment. Each drug works differently to help the immune system fight the cancer, and combining them may be more effective. **You may be eligible if...** - You are 18 or older with mantle cell lymphoma that has relapsed or not responded to at least one prior treatment (including a CD20 antibody and alkylating chemotherapy) - You have at least one measurable tumor on imaging (PET/CT scan) - You are in reasonably good health (ECOG performance status 0–1) - Your expected survival is at least 12 weeks - Tumor tissue from your most recent progression is available **You may NOT be eligible if...** - Your general health is poor - You have received certain prior treatments that overlap with these drugs - You have active serious infections or other conditions that would make treatment unsafe Talk to your doctor to see if this trial is right for you.